Compare Quest Diagnostics Inc (DGX) vs Garmin Ltd. (GRMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Garmin Ltd. — how do they compare? Quest Diagnostics Inc trades at $238.17 (market cap $26.21B), while Garmin Ltd. trades at $310.64 (market cap $59.72B). The key difference: Garmin Ltd. is far larger — about 2.3× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays the higher dividend (1.45%). Which is the better fit depends on your goals.
| DGX | GRMN | |
|---|---|---|
Market Cap | $26.21B | $59.72B |
Sector | Health | Technology |
52-Week High | $238.50 | $313.16 |
52-Week Low | $173.49 | $187.10 |
Enterprise Value | $31.97B | $57.23B |
Dividend Yield | 1.45% | 1.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.24, down 0.16% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.12 and raising its full-year outlook, driven by robust testing demand. Revenue grew to $11.04B in 2025, with net income of $992M, though margins face pressure from lower-margin deals and rising costs.
The outlook is positive due to raised guidance and AI integration enhancing efficiency, but risks include debt levels and margin compression. Analysts maintain a cautious buy stance with a $249.50 price target, indicating modest upside potential from current levels amid competitive and cost challenges.
Garmin (GRMN) trades at $310.22, down 0.94% on the day, yet maintains a bullish technical trend with strong moving averages and support near $308. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $2.81 surpassing the $2.30 estimate, driven by 11% revenue growth. Profitability remains high, with a net margin of 24.47% and ROE of 21.89%, though valuation multiples like P/E of 31.96 appear elevated. Recent news highlights surging fitness segment demand and a raised 2026 outlook.
Garmin's outlook is supported by consistent earnings outperformance and growth in wearable technology, but risks include rich valuations and potential sales deceleration. Analyst consensus is a $318.67 price target with a Hold-heavy rating, suggesting cautious optimism amid near-term strength. The stock's proximity to its 52-week high warrants monitoring for sustainability of momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →
